|View printer-friendly version|
“The use of a human tumor graft in a humanized model represents the
future of immuno-oncology research,” said
Charles River has more than 450 fully characterized proprietary PDXs in its portfolio, which represents all major tumor histotypes, and provides extensive background and characterization for oncology research. The most recent Compendium update expands the existing tumor model collection to include:
- Whole-exome mutations determined by Next-Generation Sequencing
- Gene copy number variations determined by using Affymetrix Genome-Wide Human SNP Array 6.0
- Gene expression determined by using Affymetrix Human Genome U133 Plus 2.0 Array
Recognizing the importance of selecting the appropriate tumor model for in vivo and in vitro oncology, Charles River partnered with OcellO to further expand their capabilities with PDX models. Through their agreement, OcellO utilizes human tumor material from Charles River PDX models and applies it in their 3D cell culture drug screening platform. This high-throughput platform enables the growth of micro-tumors in a natural extracellular matrix environment and uses automated 3D imaging to analyze the effects of small molecules and antibodies on tumor development.
“The extended range of tumor subtypes and high level of annotation of
Charles River’s PDX Compendium enables the selection of the optimum
tumor models with the most appropriate mutational profile for in vivo
In addition to utilizing the Compendium in integrated client relationships, recent tumor model updates have also enhanced scientific presentations. At the 2017 AACR Annual Meeting, a meeting which highlights the advances in cancer science and medicine from institutions all over the world, Charles River presented three posters highlighting the enhancement of certain models for oncology drug discovery:
- Whole-exome somatic mutation analysis of mouse cancer models and implications for preclinical immunomodulatory drug development (available here.)
- Humanized single mouse trial: A preclinical platform feasible for immune-oncology drug screening and translational biomarker development (available here.)
- In vitro PDX models: 3D cultured patient-derived tumors for compound evaluation (in conjunction with OcellO, available here.)
Charles River’s extensive portfolio of oncology products and services,
including studies in human xenograft, syngeneic, humanized immunotherapy
research models, flow cytometry, and IVIS® imaging services,
was strengthened by the acquisition of
To learn more about Charles River’s oncology research capabilities, visit www.criver.com.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations